

ASX Release

Federal Government Initiatives to Boost Medical Marijuana Industry

- **Federal Government release new initiatives to boost Medical Marijuana Industry**
- **SUDA supports these initiatives**
- **SUDA holds all key licenses to carry out R&D on Cannabis based products**

PERTH, AUSTRALIA – 7 August 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, supports the Government's initiative in relation to the medical marijuana industry.

A recent media release from Federal Health Minister Greg Hunt stated that the Federal Government will boost the national medical marijuana industry by prioritising major project status projects for medical marijuana licences. Medical marijuana licences would be granted through the Department of Health's Office of Drug Control (ODC) from 1 September 2019 and the Government will be looking at ways to remove congestion that blocked administration and development of the industry and would work towards a single licence model.

The ODC currently manages the licenses for the cultivation, production and supply of medicinal cannabis and has so far issued 24 licenses for cultivation of cannabis for medicinal use; 16 for cultivation for research; and 23 for manufacture of medicinal cannabis products.

SUDA has been building its infrastructure to carry out research into Medical Marijuana and now holds the following licences, issued either by the Government of Western Australia or the ODC, in relation to its cannabinoid projects:

- Permit to purchase cannabis and cannabinoids for the purpose of research and education;
- Wholesale Warehousing licence to allow supply of medicines (including cannabis) for use in clinical trials;
- Good Manufacturing Practice Licence to allow the production of early stage clinical samples (up to Phase 1) and release for supply
- Permit to purchase and possess cannabidiol, tetrahydrocannabinols and cannabinoids; and
- To import and export cannabis and cannabinoid products

In December 2018, SUDA signed an agreement with Zeldia Therapeutics to develop an oral spray of pharmaceutical-grade cannabinoid derivatives. In June 2019, SUDA signed a binding term sheet with Cann Pharmaceutical Australia (CPA) to develop and supply an oral spray of pharmaceutical-

grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma and motion sickness. SUDA and CPA are currently in the process of finalising the agreement.



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; PAH; epileptic seizures and pre-procedural anxiety; and cancer. SUDA is also fully licensed to purchase and manufacture cannabinoid products. For more information, visit www.sudapharma.com